New longer-term results show a survival benefit from adding the immune checkpoint inhibitor pembrolizumab (Keytruda) to first-line chemotherapy for women with metastatic triple-negative breast cancer

Read more

Long-term results give a resounding yes to the question of whether radiotherapy reduces the risk of recurrence over observation alone in women with good-risk ductal

Read more

NEW YORK (Reuters Health) – The American Joint Committee on Cancer (AJCC)’s pathologic prognostic staging system low-risk Recurrence Score (RS) for downstaging breast cancer should

Read more